Physician profile
Michael Yeh
NPI 1265458954
$9,099.62
in general payments reported to CMS, 2019-2025
36 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,497 · 2020: $1,126 · 2021: $2,728 · 2022: $615 · 2023: $319 · 2024: $354 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,151.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,093.24 | 2019-2025 | |
| Amgen INC. | $887.19 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $577.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.91 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $504.00 | 2021-2025 | Verquvo |
| Pfizer INC. | $465.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $465.38 | 2019-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $370.67 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| E.R. Squibb & Sons, L.L.C. | $298.54 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $271.40 | 2019-2021 | |
| Amarin Pharma, INC. | $270.30 | 2019-2021 | |
| Lundbeck LLC | $201.72 | 2019-2020 | |
| Esperion Therapeutics, INC. | $183.70 | 2020-2022 | |
| Cvrx, INC. | $103.61 | 2022-2025 | Barostim Neo System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $93.12 | 2020-2025 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.40 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $65.97 | 2025 | Assure Wcd |
| Arbor Pharmaceuticals, INC. | $65.60 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $60.34 | 2019-2025 | Amvuttra |
| Xeris Pharmaceuticals, INC. | $35.57 | 2021 | |
| United Therapeutics Corporation | $35.55 | 2021-2022 | |
| Edwards Lifesciences Corporation | $30.56 | 2020 | |
| Impulse Dynamics (USA) INC. | $27.75 | 2024 | Optimizer |
| Tactile Systems Technology INC | $27.36 | 2020 | |
| Gilead Sciences, INC. | $21.50 | 2019 | |
| Boston Scientific Corporation | $19.33 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $18.80 | 2021 | |
| Glaxosmithkline, LLC. | $18.78 | 2025 | Shingrix |
| Lexicon Pharmaceuticals, INC. | $18.38 | 2024 | |
| Angiodynamics, INC. | $17.26 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.65 | 2021 | |
| Medtronic, INC. | $15.23 | 2021 | |
| Amryt Pharma Holdings Ltd | $15.13 | 2021 | |
| Irhythm Technologies, INC. | $14.35 | 2021 | |
| Bardy Diagnostics, INC. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.